View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 21, 2020updated 24 Feb 2020 5:47am

Covid-19: First coronavirus vaccine trial submission expected in April

The earliest vaccine for the novel coronavirus in China will be submitted for clinical trials around late April, said China’s Vice Minister of Science and Technology Xu Nanping at a press conference.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

The earliest vaccine for the novel coronavirus in China will be submitted for clinical trials around late April, according to China’s vice-minister of science and technology Xu Nanping.

SARS-CoV-2, the new coronavirus that emerged in Wuhan, China in December 2019, has claimed the lives of more than 2,200 people and led to over 76,000 infections across 28 countries.

Companies and researchers worldwide are in a race to develop a vaccine and also effective treatments for the disease caused by SARS-CoV-2, officially named as Covid-19.

While various existing drugs have entered clinical trials, vaccine candidates are still in development or preclinical stages. It is estimated that a coronavirus vaccine will take nearly a year to be market-ready.

See all Coronavirus vaccines and drugs in the pipeline

Initial drug data expected within weeks

In a tweet, the World Health Organization director-general Tedros Adhanom Ghebreyesus said that initial data from the clinical trials of AbbVie’s lopinavir plus ritonavir, and Gilead’s remdisivir is expected to be available in three weeks.

These drugs are prioritised by the WHO R&D Blueprint.

The drugs hold approvals for other indications, allowing them to bypass safety tests in animals. Two accelerated trials are being conducted based on the WHO expert recommendations, reported the Guardian.

A study by the US National Institutes of Health (NIH) demonstrated that Gilead’s antiviral drug, remdesivir, could prevent a type of coronavirus in monkeys.

The drug prevented the Middle East respiratory syndrome coronavirus (MERS-CoV) disease when administered before infection. In infected animals, the drug improved their condition.

In a separate development, China Daily reported that the combination of traditional Chinese medicine with Western drugs has demonstrated effectiveness against the new coronavirus.

State Administration of Traditional Chinese Medicine head was quoted as saying: “A large number of clinical practices have confirmed the effect of the combined treatment of TCM and Western medicine on new coronavirus pneumonia patients.”

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy